ABVC BioPharma (NASDAQ:ABVC) Trading 0.9% Higher – Should You Buy?

Shares of ABVC BioPharma, Inc. (NASDAQ:ABVC) were up 0.9% during mid-day trading on Friday . The stock traded as high as $1.10 and last traded at $1.09. Approximately 68,611 shares were traded during mid-day trading, a decline of 7% from the average daily volume of 73,972 shares. The stock had previously closed at $1.08.

Wall Street Analyst Weigh In

Separately, Weiss Ratings cut ABVC BioPharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 1st. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

ABVC BioPharma Trading Up 0.9%

The stock has a fifty day simple moving average of $1.20 and a two-hundred day simple moving average of $1.86. The company has a market cap of $27.73 million, a PE ratio of -2.73 and a beta of 0.42.

ABVC BioPharma (NASDAQ:ABVC) last announced its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.11) earnings per share for the quarter.

Institutional Investors Weigh In On ABVC BioPharma

Institutional investors have recently modified their holdings of the company. Geode Capital Management LLC boosted its stake in shares of ABVC BioPharma by 7.7% during the 4th quarter. Geode Capital Management LLC now owns 202,365 shares of the company’s stock worth $431,000 after acquiring an additional 14,553 shares in the last quarter. Millennium Management LLC purchased a new stake in shares of ABVC BioPharma during the 3rd quarter worth approximately $60,000. Finally, Citadel Advisors LLC purchased a new stake in shares of ABVC BioPharma during the 3rd quarter worth approximately $48,000. Hedge funds and other institutional investors own 11.38% of the company’s stock.

ABVC BioPharma Company Profile

ABVC BioPharma is a clinical-stage biotechnology company focused on the discovery and development of novel vaccine and immunotherapy candidates for oncology and infectious diseases. The company leverages a proprietary peptide-based platform to identify and synthesize immunogenic epitopes, aiming to stimulate targeted immune responses against tumor-associated and pathogen-derived antigens.

The company’s pipeline includes active immunotherapy programs designed to address a range of cancer indications, along with vaccine candidates targeting bacterial pathogens.